US Stock Market Move | Lower the price of small bottles of the weight loss drug Zepbound, Eli Lilly (LLY.US) rises more than 2% against the trend.
On Tuesday, Eli Lilly (LLY.US) rose against the trend by more than 2%, closing at $902.26.
On Tuesday, Eli Lilly (LLY.US) defied the trend with a rise of over 2%, closing at $902.26. In terms of news, Eli Lilly is increasing its efforts to combat cheap Zepbound counterfeit products. The company announced on its official website that it will lower the price of the popular weight-loss drug Zepbound in "small bottle" form. According to a statement, the company will reduce the prices of the 2.5 mg and 5 mg Zepbound bottles to $349 and $499 per month, respectively. This is about $50 lower than the current prices.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
